Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2012

Biomarker Diagnostics Firm Astute Raises $40.4M in Series C Fundraising

  • Astute Medical raised $40.4 million in a Series C round of financing led by MPM Capital, and including existing investors and new investor Kaiser Permanente Ventures. The firm says it will use the funds to start commercializing its first product, progress R&D, and validate biomarker-based laboratory tests.

    Founded in 2007, Astute is focused on the identification and validation of protein biomarkers as the basis for in vitro diagnostic tests. The firm’s primary areas of interest are community and hospital acquired acute conditions that require rapid diagnosis and risk assessment, and disorders including abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis.

    The firm completed a $26.5 million Series B financing in 2010, and last year extended the round by raising another $13 million. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »